TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10533157

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 9083869

Group type: EXPERIMENTAL
Intervention: MgSO4 (200 mEq for the first 5 postoperative days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1805974

Group type: EXPERIMENTAL
Intervention: Crystalline pure lactulose (Laevolac Cristalli)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Powder pure lactitol
Number of subjects: 40
Study: 6649975

Group type: EXPERIMENTAL
Intervention: Intravenous Metronidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous Metronidazole combined with intravenous Gentamycin
Number of subjects: 0
Study: 31321427

Group type: EXPERIMENTAL
Intervention: Medication cost transparency alerts for high-cost medications
Number of subjects: 1896
Study: 28139972

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 4426

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 4426

Group type: EXPERIMENTAL
Intervention: AR-C124910XX 60 mg twice daily
Number of subjects: 4426

Group type: EXPERIMENTAL
Intervention: AR-C124910XX 90 mg twice daily
Number of subjects: 4426

Group type: EXPERIMENTAL
Intervention: Demographic subgroups (body weight, sex, age, smoking, Japanese ethnicity)
Number of subjects: 4426

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4426
Study: 26185899

Group type: EXPERIMENTAL
Intervention: Fixed appliances (brackets and archwires)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Removable appliances (acrylic plates and protruding springs)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both groups (fixed and removable appliances)
Number of subjects: 62
Study: 24499951

Group type: EXPERIMENTAL
Intervention: FTC/TDF (Tenofovir disoproxil fumarate coformulated with emtricitabine)
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499
Study: 22848766

Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel (PZQ)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 75 mg/kg praziquantel (PZQ)
Number of subjects: 93
Study: 20673554

Group type: EXPERIMENTAL
Intervention: Adjunctive armodafinil 150 mg/d
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 19031646

Group type: EXPERIMENTAL
Intervention: Manual instrumentation with stainless steel files
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical instrumentation with RaCe rotary nickel‐titanium instruments
Number of subjects: 40
Study: 16337461

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 200 microg twice daily
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 200 microg once daily
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg 3 times daily
Number of subjects: 981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study: 12520835

Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline (epinephrine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0
Study: 9606780

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 7898178

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 128
Study: 2794177

Group type: EXPERIMENTAL
Intervention: Structural family therapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Psychodynamic child therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Recreational control condition
Number of subjects: 69
Study: 117789

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral (Milk) feeding
Number of subjects: 40
Study: 31522922

Group type: EXPERIMENTAL
Intervention: Subsidized community-supported agriculture membership (weekly farm produce pickup from June to November)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Healthy eating information (control group)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Subsidized community-supported agriculture membership
Number of subjects: 128
Study: 29212716

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25851629

Group type: EXPERIMENTAL
Intervention: CYT107 before chemotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CYT107 during chemotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo before chemotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo during chemotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CYT107 and Placebo
Number of subjects: 20
Study: 23547623

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate solution (CHO) given in the evening prior to surgery and 2-3 hours before anesthesia.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine fasting (Control group).
Number of subjects: 60
Study: 21685651

Group type: EXPERIMENTAL
Intervention: Interactive VR condition where participants could manipulate the VR figure.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Passive VR condition where participants observed the VR figure.
Number of subjects: 94

Group type: COMPARATOR
Intervention: No VR exposure (control condition).
Number of subjects: 94
Study: 18998190

Group type: EXPERIMENTAL
Intervention: Caregivers (primary/most)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Caregivers with depressive symptoms
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Caregivers with low social support
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Caregivers of cardiac patients
Number of subjects: 263
Study: 16430351

Group type: EXPERIMENTAL
Intervention: PhoenixCare intervention (intensive home‐based case management by registered nurse case managers)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: PhoenixCare intervention
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (usual MCO care)
Number of subjects: 192
Study: 15238183

Group type: EXPERIMENTAL
Intervention: Pressure Controlled Ventilation (PCV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Volume Controlled Ventilation (VCV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both PCV and VCV
Number of subjects: 50
Study: 11386854

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (4-6 mg/kg) and carbidopa (0.5-1.0 mg/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: l-tryptophan (50-70 mg/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (1 mg/kg)
Number of subjects: 5
Study: 9219480

Group type: EXPERIMENTAL
Intervention: Gelseal (gelatin‐sealed knitted Dacron prosthesis, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hemashield (collagen‐sealed woven Dacron prosthesis, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gelseal
Number of subjects: 60
Study: 8273320

Group type: EXPERIMENTAL
Intervention: Fleet enema
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dulcolax micro‐enema
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dulcolax suppository
Number of subjects: 96

Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 96
Study: 3689477

Group type: EXPERIMENTAL
Intervention: Increasing saturated to unsaturated fat ratio (S:U)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Absorbed cholesterol from sources other than eggs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Absorbed cholesterol from eating eggs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Absorbed cholesterol from all sources including eggs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Saturated to unsaturated fat ratio (S:U)
Number of subjects: 24
Study: 29172029

Group type: EXPERIMENTAL
Intervention: 2 × 20‐s sprints
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2 × 10‐s sprints
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 26476074

Group type: COMPARATOR
Intervention: Brackets bonded with primer (Transbond™ MIP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Brackets bonded without primer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Brackets bonded without primer in younger patients (10-13 years)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Brackets bonded with primer in younger patients (10-13 years)
Number of subjects: 50
Study: 24768116

Group type: EXPERIMENTAL
Intervention: COP velocity
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ellipse area
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: COP measures during arm raise
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: COP velocity and ML displacement
Number of subjects: 42
Study: 22343600

Group type: EXPERIMENTAL
Intervention: Pressure-relieving suspension boot (Heelift; DM Systems Inc, Evanston, Illinois)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous bags
Number of subjects: 30
Study: 18550225

Group type: EXPERIMENTAL
Intervention: Elderly individuals (≥ 65 years)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Survivors of SCI
Number of subjects: 485

Group type: COMPARATOR
Intervention: Postmortem spinal cord tissue analysis
Number of subjects: 485
Study: 18516889

Group type: EXPERIMENTAL
Intervention: Fentanyl 15 microg x hr(‐1) in ropivacaine (group F3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 0 microg x hr(‐1) in ropivacaine (group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 microg x hr(‐1) in ropivacaine (group F1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg x hr(‐1) in ropivacaine (group F2)
Number of subjects: 60
Study: 16767414

Group type: EXPERIMENTAL
Intervention: Pergolide (0.075 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14687346

Group type: EXPERIMENTAL
Intervention: Intense tai chi (TC) exercise program
Number of subjects: 311

Group type: COMPARATOR
Intervention: Wellness education (WE) program
Number of subjects: 311
Study: 10955373

Group type: EXPERIMENTAL
Intervention: NK-104 2 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NK-104 4 mg/day
Number of subjects: 30
Study: 8617706

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day titrated to 200 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1345039

Group type: EXPERIMENTAL
Intervention: Ch (concentration of allergen eliciting a wheal of the same size as histamine)
Number of subjects: 36
Study: 6708530

Group type: EXPERIMENTAL
Intervention: [3H]progesterone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: [125I]tracer
Number of subjects: 14
Study: 31058607

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (AKI e‐alerts, AKI care bundle, education program)
Number of subjects: 24059

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24059
Study: 28876332

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) supplementation
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Multivitamin (MV) supplementation
Number of subjects: 589
Study: 26987818

Group type: EXPERIMENTAL
Intervention: Behavioural change programme (BCP) with ongoing active reinforcement and enhanced provision of moisturising cream
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care with provision of an advice leaflet about optimal hand care
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Behavioural change programme (BCP)
Number of subjects: 35
Study: 24918298

Group type: EXPERIMENTAL
Intervention: Functional Isometric (FI) Squats
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dynamic Half (DH) Squats
Number of subjects: 10

Group type: COMPARATOR
Intervention: Combined Condition Data (FI and DH)
Number of subjects: 10
Study: 21962986

Group type: EXPERIMENTAL
Intervention: Two consecutive meals
Number of subjects: 12
Study: 20203096

Group type: EXPERIMENTAL
Intervention: Memory training (12 hr)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Health training (12 hr)
Number of subjects: 265
Study: 17476142

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to palliative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Involvement of radiation oncologists in palliative care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: National and professional society efforts
Number of subjects: 0
Study: 15361263

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine for 8 weeks
Number of subjects: 369
Study: 11832253

Group type: EXPERIMENTAL
Intervention: HADS-A (Anxiety)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: HADS-D (Depression)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: HADS-D
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: HADS-D and HADS-A
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: HADS-D item D4 (slowed down)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: HADS-A and MCS
Number of subjects: 736
Study: 10362441

Group type: EXPERIMENTAL
Intervention: Metrifonate 50 mg once daily
Number of subjects: 264
Study: 8808221

Group type: EXPERIMENTAL
Intervention: 1.75 mmol/l calcium dialysate
Number of subjects: 14

Group type: COMPARATOR
Intervention: 1.25 mmol/l calcium dialysate
Number of subjects: 14
Study: 2020143

Group type: EXPERIMENTAL
Intervention: Cardioplegic solution (Bretschneider) in Group A
Number of subjects: 427

Group type: COMPARATOR
Intervention: Intermittent aortic cross‐clamping in Group B
Number of subjects: 427
Study: 6749425

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30040013

Group type: EXPERIMENTAL
Intervention: Compression socks (SOCK)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CONTROL)
Number of subjects: 20
Study: 29150147

Group type: EXPERIMENTAL
Intervention: LAUNCH (18-session clinic and home-based behavioral intervention)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Motivational interviewing (delivered at the same frequency as LAUNCH)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard care (no formal intervention)
Number of subjects: 151
Study: 26683683

Group type: EXPERIMENTAL
Intervention: Blinatumomab (9-μg/day continuous i.v. infusion on days 1-7 and 28-μg/day continuous i.v. infusion on days 8-28 for Cycle 1; subsequent cycles 28-μg/day continuous i.v. infusion on days 1-28)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 21
Study: 25054594

Group type: EXPERIMENTAL
Intervention: Weekly interdisciplinary program (WIP) consisting of educational activities, physical therapy, stretching, ergonomics, posture guidance, cognitive behavioral strategies.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pain Clinic referral (Control group)
Number of subjects: 27
Study: 22209391

Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily (1 previous VEGFr-TKI)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily (2 previous VEGFr-TKI)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo (1 previous VEGFr-TKI)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo (2 previous VEGFr-TKI)
Number of subjects: 416
Study: 21157173

Group type: EXPERIMENTAL
Intervention: Gauze frozen with normal saline (n=17)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gauze frozen with ice (n=18)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wet gauze (n=18)
Number of subjects: 53
Study: 17977237

Group type: EXPERIMENTAL
Intervention: keepin' it REAL program
Number of subjects: 4622
Study: 15507793

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin daily for 6 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin
Number of subjects: 55
Study: 11835701

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32-34 degrees C) in Group B
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normothermia (control group) in Group B
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32-34 degrees C) in Group A
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normothermia (control group) in Group A
Number of subjects: 44
Study: 9744663

Group type: EXPERIMENTAL
Intervention: TENS (100 Hz, tolerable intensity)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 60
Study: 7917695

Group type: EXPERIMENTAL
Intervention: Prophylactic medication (pirenzepine)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Prophylactic medication (famotidine)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (either pirenzepine or famotidine)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (first 36 patients without prophylactic medication)
Number of subjects: 79
Study: 3126637

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) patch 5 mg/24 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) patch 10 mg/24 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 24
Study: 30703703

Group type: EXPERIMENTAL
Intervention: Physical activity interventions
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Global cognition
Number of subjects: 75
Study: 28360247

Group type: EXPERIMENTAL
Intervention: Thrice weekly aerobic exercise training (AT) for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Thrice weekly aerobic exercise training (AT)
Number of subjects: 70
Study: 25481281

Group type: EXPERIMENTAL
Intervention: Expert-generated schemas
Number of subjects: 57

Group type: COMPARATOR
Intervention: Traditional teaching frameworks
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Learner-generated schemas
Number of subjects: 57
Study: 24308234

Group type: EXPERIMENTAL
Intervention: Cold lateral condensation technique
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Thermafil technique
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ProTaper gutta‐percha
Number of subjects: 45
Study: 21942708

Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60)
Number of subjects: 121

Group type: COMPARATOR
Intervention: LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61)
Number of subjects: 121
Study: 19220089

Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline (500 mg in 500 mL saline for 2 hours followed by 700 mg in 1000 mL saline for 6 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (1500 mL saline)
Number of subjects: 32
Study: 15176496

Group type: EXPERIMENTAL
Intervention: Orally inhaled fluticasone propionate (FP) 88 or 220 microg via metered-dose inhaler (MDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally inhaled fluticasone propionate (FP) 250 microg via Diskus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally inhaled fluticasone propionate (FP) 250 microg/salmeterol 50 microg via Diskus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal fluticasone propionate (FP)
Number of subjects: 0
Study: 10404811

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol (50 microg) for 6 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Estradiol in combination with oral norethisterone (1 mg) for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matching placebo patches for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matching oral placebo preparation for 6 weeks
Number of subjects: 22
Study: 7564870

Group type: EXPERIMENTAL
Intervention: Omeprazole (OM) 20 mg mane
Number of subjects: 55

Group type: COMPARATOR
Intervention: Ranitidine (RAN) 300 mg nocte
Number of subjects: 55
Study: 2406538

Group type: EXPERIMENTAL
Intervention: Fructose 1,6-diphosphate (FDP) infusion (250 mg.kg-1 body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 6111083

Group type: EXPERIMENTAL
Intervention: 10 mg pindolol combined with 5 mg clopamide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol combined with 12.5 mg hydrochlorothiazide
Number of subjects: 10
Study: 31986288

Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) infusion at rates of 9.4 mmol/h, 12 mmol/h, or 15 mmol/h
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 113
Study: 31228782

Group type: EXPERIMENTAL
Intervention: Respirator Intervention Phase (RIP) with facemask
Number of subjects: 39

Group type: COMPARATOR
Intervention: No Intervention Phase (NIP)
Number of subjects: 39
Study: 28587952

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 60mg loading dose at admission, followed by 20mg three times a day
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (no TMZ)
Number of subjects: 173
Study: 27354782

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 15.6 µg
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 24142687

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21733320

Group type: COMPARATOR
Intervention: 15 μg cholecalciferol per day
Number of subjects: 212
Study: 19684238

Group type: EXPERIMENTAL
Intervention: Experimental group (received removed disc fragments)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (did not receive removed disc fragments)
Number of subjects: 74
Study: 17852442

Group type: EXPERIMENTAL
Intervention: Alternating therapy with DFP at 75 mg/kg/day for 4 days/week and DFO at 40 mg/kg/day for 5-7 nights/week
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alternating therapy with DFP and DFO
Number of subjects: 60

Group type: COMPARATOR
Intervention: DFO alone
Number of subjects: 60